AVE (Avemar) - 30 pack - 8.5 GM

$179.95    $143.97

Quantity   1 - 2    3 - 5    6 - 8    9+  
Price $143.97 $133.97 $123.97 $113.97
products/abs/avemar_125.jpg

AVE (Avemar) - 30 packets - 8.5 GM by American BioScience

Dietary supplement, naturally orange flavored instant drink mix, 30 single use packets per box, each providing 8.5 grams Avemar pulvis.

Avé, the dietary supplement with Avemar®, is a uniquely beneficial natural compound that has been the subject of more than 20 peer-reviewed publications describing in vitro, in vivo and human clinical trials.

Avemar is made from wheat germ fermented by baker’s yeast through a patented process (US patent# 6,355,474), standardized for DMBQ. Studies conducted in the US, Hungary, Israel, Italy, Austria and Russia with Avemar prove Dr. Szent-Györgyi theories correct, with such dramatic results, its hard to believe its all-natural.

When ordering AVE (Avemar) be sure to select 1st. or 2nd. day air. This product is best to be shipped with a cold pack on Monday, Tuesday or Wednesday. The product will remain stable in room temperature but best kept in the refrigerator as we do here at Healing*Edge Science.

From Nobel Prize to Prized Supplement . . .

Avemar's development was inspired by the work of Hungarian scientist Dr. Albert Szent-Györgyi, awarded the 1937 Nobel Prize in Medicine for describing the essential role of vitamin C in the life-sustaining processes of cellular metabolism.

Dr. Szent-Györgyi recognized that methoxy-substituted benzoquinones play essential roles in regulating and fine tuning metabolism at the cellular level and theorized that supplemental levels of methoxy-substituted benzoquinones could help the body respond to internal and external stresses.

In recent years, a new generation of Hungarian scientists has continued Dr. Szent-Györgyi's work by developing a method of manufacturing an all-natural and standardized source of methoxy-substituted benzoquinones by fermenting wheat germ with baker's yeast through a patented process. (U.S. Patent #6,355,474).

This product is now available as a dietary supplement in a once-a-day, pleasant tasting instant drink mix, and is being studied in hospitals and recommended by doctors around the world. It is available in the U.S. under the brand name Avé, and as Avemar outside the U.S.

How does Avé work?

1. Avé Supports Cell Metabolic Regulation
2. Avé Promotes Immune System Regulation
* Enhance the ability of T-cells to respond to antigen presentation, and B-cells to respond to activation and produce appropriate antibodies
* Normalize balance of cellular and humoral (Th1/Th2) immune function
* Enhance Macrophage functioning
3. Avé Enhances NK Cell Targeting
Avemar helps the immune system identify invaders for attack. Immune system enemy invaders try to hide from the immune system’s Natural Killer (NK) cells by displaying a surface molecule called MHC-1.
MHC-1 tells NK cells, “don’t attack me, I’m one of the good guys,…but, research shows Avemar suppresses the invading cell’s “mask” (MHC-1) resulting in increased NK cell targeting and immune system clearing.

Avé, dietary supplement from American BioSciences, named “Best New Product of the Year”

(Blauvelt, NY) American BioSciences, Inc. has earned the “Best New Product of the Year Award” for its dietary supplement product Avé™. The award, called “NutrAward,” was presented at the annual Natural Products Expo
West/SupplyExpo 2006 tradeshow in Anaheim California, the largest gathering of the natural, organic and healthy product industry. Avé was introduced in May of 2005 and is the first supplement to use the novel nutritional
ingredient Avemar® which has been shown to provide health benefits by supporting mechanisms of healthy cell metabolism and immune system regulation that are altered by injury and physical stress. “Over 15,000 new products or ingredients are introduced into the natural products market every year,” said Todd Runestad, Science Editor of Functional Foods & Nutraceuticals magazine, which covers the industry. Companies were invited to submit new products for NutrAward consideration by an independent panel of industry experts and medical and scientific researchers, who narrowed the field to three semifinalists by judging each on six criteria: scientific merit, efficacy, safety, innovation, market potential and ability to increase industry credibility. The final NutrAward winner was determined by the vote of the 44,000 attendees of the 25th annual Expo West/SupplyExpo tradeshow.

The NutrAward is highly valued within the industry. Companies seeking to win it must submit the research conducted on their products to a rigorous scientific review performed by independent industry and academic experts in
natural products. “We have been in the forefront of encouraging companies to make comments about their products based on science, so we take a look at things pretty critically, and the Avé and Avemar products looked good in that context,” said Richard D. Kreider, PhD, Professor and Chair of the Department of Health, Human Performance and Recreation, Director of the Exercise and Sport Nutrition Laboratory at Baylor University, and a member of the Nutracon scientific review panel. “There were data from both animal and human clinical trials to validate Avemar's safety and efficacy.” He also commented, “The studies were well done, from both the theoretical and
applied standpoints, and the results showed it had both mechanistic and overall immunological impact.” The Avemar science reviewed by the expert panel included results of over 100 experiments in cell lines, animal and human subjects, described in more than 20 publications in peer-reviewed medical journals such as the British Journal of Cancer, Pancreas, The International Journal of Oncology, Lupus, Nature Biotechnology, and others. Studies conducted in the US, Hungary, Israel, Russia and other countries show the compound works to optimize metabolism and immune system function in conditions in which either or both are challenged. Use of Avemar as a dietary supplement has been shown to support mechanisms of cell metabolic regulation, so that cells in our bodies use glucose, their basic fuel source, at a steady rate through healthy oxidative pathways. Healthy metabolic rate and pathways can be altered by injury and stress resulting in a variety of health conditions. Injury and stress can also alter immune response, and Avemar has been shown to support mechanisms of innate and acquired immune system regulation. Avemar use improves the balance of cellular and humoral immune activity, the ratio of Th1 and Th2 cytokines, promotes optimal NK (Natural Killer) cell recognition, and the coordinated response of macrophages, B-cell and T-cells.

In Hungary, where Avemar was invented and where it is manufactured, Avemar is classified as a “medical food,” and is a standard treatment and approved therapy for many health conditions. It is available as a food product or dietary supplement in many European and Asian countries. American BioSciences completed the US FDA process of establishing Avemar as GRAS (Generally Recognized As Safe) a designation that allows its use in foods, beverages and dietary supplements. Avé is a dietary supplement instant drink mix and is the first US product to contain Avemar. “We are very pleased to see the prestigious 2006 NutrAward added to the recognition Avemar and Avé have received,” said David Wales, President of American BioSciences. Earlier this year, Avé received the “Product Merit Award” from the Nutrition Business Journal, an industry trade journal. In Hungary, the development of Avemar was honored by the awarding of the President’s Gold Medal of Merit to its inventor Dr. Mate Hidvegi. “It is our hope that the publicity of winning the NutrAward will bring Avé and the research behind Avemar to the attention of a broader spectrum of the public and medical community and provide new health care opportunities,” added Rick Jahnke, vice-president and co-founder of American BioSciences “It has always been our goal to focus first and foremost on helping people achieve their health potential. We work with university and private researchers to identify extremely well researched natural compounds that have never been marketed as natural compounds, often because synthetic versions of them are on track for drug development. Avé and Avemar prove that the science of natural compounds can rise to the level of the most powerful drug compounds, but without toxicity issues because they are basically food compounds. The dietary supplements we sell are the same compounds used in the research, and peer-reviewed publications provide accurate, third party information on safety and efficacy.”
Avemar research can be found by searching the National Institutes of Health website, www.pubmed.org, with the search term, Avemar, and/or “fermented wheat germ.


Serving Size

1 packet , 30 servings per container

Suggested Use

As a dietary supplement, recommended usage is one Ave packet per day, mixed with 8 oz (240 ml) of cold water ( or any other beverage containing less than 10 mg of vitamin C). Mixing is best accomplished by shaking in a closed container (add liquid first, then Ave, close lid and shake). It is best to consume within 30 minutes of mixing. Ave should be consumed one hour before or after a meal, and two hours before or after any drugs or other dietary supplements. For best results use Ave daily. For people over 199 lbs, the recommendation is to use two packets per day. Please consult with a healthcare professional for recommended usage levels for children, for guidance on alternative usage levels, and use in combination with other dietary supplements.

Warnings/Cautions

Women who are pregnant or nursing should not consume Ave. It should not be consumed by people who have had an organ or tissue transplant, by those suffering from bleeding GI ulcers, malabsorption syndrome, gluten sensitive enterophaties (celiac sprue), fructose intolerance or who have hypersensitivity to gluten, wheat germ or any of the components or ingredients in this product. It is recommended to discontinue Ave usage 2 days before barium X-ray contrast examinations and resume 2 days after the completion of the examination.

Supplement Facts

Serving Size is 1 packet
Amount Per Serving %DV
Calories 60g *
Total Carbohydrates 13g *
Sugars 13g *
Protein 2g *
Thiamin (Vitamin B-1) 320mcg *
Vitamin B-6 120mcg *
Calcium 24mg *
Iron 1125mcg *
Phosphorous 135mg *
Magnesium 45mg *
Zinc 1170mcg *
Copper 41mcg *
Manganese 2250mcg *
Chromium 5mcg *
Molybdenum 13mcg *
Sodium 24mg *
Potassium 153mg *
flavonoids 500mcg *
bioquinones, polyephenols 464mg *
*Daily Value (DV) not established.


Human Clinical Trials
1. Garami M, Schuler D, Babosa M, Borgulya G, Hauser P, Müller J, Paksy A, Szabó E, Hidvégi M, Fekete G.: Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients, J Pediatr Hematol Oncol 26 (10), October 2004.
Click to view full text
2. Jakab F, Shoenfeld Y, Balogh A, Nichelatti M, Hoffmann A, Kahan Z, Lapis K, Mayer A, Sapy P, Szentpetery F, Telekes A, Thurzo L, Vagvolgyi A, Hidvegi M.: A medical nutriment has supportive value in the treatment of colorectal cancer, Br J Cancer 2003 Aug 4;89(3):465-9.
Click to view full text
3. Demidov LV, Manzjuk LV, Kharkevitch GY, Artamonova EV, Pirogova NA: Antimetastatic effect of Avemar in high-risk melanoma patients. 18th UICC International Cancer Congress, Oslo, Norway, 30 June – 5 July, 2002. (Abstract). Int J Cancer 2002; 100(S13): 408.
Click to view full text
4. Jakab F, Mayer F, Hoffman A, Hidvegi M: First Clinical Data of a Natural Immunomodulator in Colorectal Cancer, Hepato-Gastroenterology 2000; 47:393-395
Click to view full text


Review articles
5. Boros LG, Nichelatti M, Shoenfeld Y.: Fermented Wheat Germ Extract (Avemar) in the Treatment of Cancer and Autoimmune Diseases. Ann N Y Acad Sci. 2005 Jun;1051:529-542.
Click to view full text

6. Telekes A, Kiss-Toth E, Nagy T, Qwarnstrom EE, Kusz E, Polgar T, Resetar A, Dower SK, Duda E.: Synergistic effect of Avemar on proinflammatory cytokine production and ras-mediated cell activation. Ann N Y Acad Sci. 2005 Jun;1051:515-28.
Click to view full text

7. Sukkar SG, & Edoardo R: Oxidative stress and nutritional prevention in autoimmune rheumatic diseases, Autoimmunity Reviews 3 (2004) 199–206
Click to view full text
8. Nichelatti M, Hidvégi M: Experimental and clinical results with Avemar (a dried extract from fermented wheat germ) in animal cancer models and in cancer patients. Nogyógyászati Onkológia 7: 180-185, 2002.
Click to view full text
9. Cascante M, Boros LG, Comin-Anduix B, Atauri P, Centelles JJ, Lee W-NP: Metabolic control analysis in drug discovery and disease. Nature Biotechnol 20: 243-249, 2002.
Click to view full text
10. Boros LG, Lee W-NP, Go VLW: A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas 24: 26-33, 2002.
Click to view full text
11. Boros LG, Cascante M, Lee W-NP: Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discovery Today 7(6), 18-26, 2002.
Click to view full text


In vivo (animal studies)
12. Szende B, Marcsek Z, Kocsis Z, Tompa A: Effect of Simultaneous Administration of Avemar® and Cytostatic Drugs on Viability of Cell Cultures, Growth of Experimental Tumors, and Survival of Tumor-Bearing Mice, Cancer Biother Radiopharm Volume 19, Number 3, 2004.
Click to view full text
13. Zalatnai A, Lapis K, Szende B, Rásó E, Telekes A, Resetár Á, Hidvégi M: Wheat germ extract inhibits experimental colon carcinogenesis in F-344 rats. Carcinogenesis 22: 1649-1652, 2001.
Click to view full text
14. Ehrenfeld M, Blank M, Shoenfeld Y, Hidvegi M: AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease. Lupus 10: 622-627, 2001.
Click to view full text
15. Hidvégi M, Rásó E, Tömösközi-Farkas R, Szende B, Paku S, Prónai L, Bocsi J, Lapis K: MSC, a new benzoquinone-containing natural product with antimetastatic effect. Cancer Biother Radiopharm 14: 277-289, 1999.
Click to view full text
16. Hidvégi M, Rásó E, Tömösközi-Farkas R, Lapis K, Szende B: Effect of MSC on the immune response of mice. Immunopharmacology 41: 183-186, 1999.
Click to view full text
17. Hidvégi M, Rásó E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B: Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals. Anticancer Res 18: 2353-2358, 1998.
Click to view full text


In vitro (cell line studies)
18. Illmer C, Madlener S, Horvath Z, Saiko P, Losert A, Herbacek I, Grusch M, Krupitza G, Fritzer-Szekeres M, Szekeres T.: Immunologic and biochemical effects of the fermented wheat germ extract Avemar, Exp Biol Med (Maywood) 2005 Feb;230(2):144-9.
Click to view full text
19. Tompa A, Kocsis Zs, Marcsek Z, Jakab M, Szende B & Hidvégi M: Chemoprevention with Tamoxifen and Avemar® by Inducing Apoptosis on MCF-7(ER+) Breast Cancer Cells, Proceedings of the 2nd Congress of the World Society for Breast Health, Budapest, June 24-28, 2004.
Click to view full text
20. Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A.: The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment, Cancer Biother Radiopharm 2004 Dec;19(6):746-53.
Click to view full text
21. Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, Vizler Cs, Telekes A, Resetár Á, Monostori É: Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol 20: 563-570, 2002.
Click to view full text
22. Comín-Anduix B, Boros LG, Marin S, Boren J, Callol-Massot C, Centelles JJ, Torres JL, Agell N, Bassilian S, Cascante M: Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J Biol Chem 277: 46408-46414, 2002.
Click to view full text
23. Boros LG, Lapis K, Szende B, Tömösközi-Farkas R, Balogh Á, Boren J, Marin S, Cascante M, Hidvégi M: Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells. Pancreas 23: 141-147, 2001.
Click to view full text
24. Kiss-Toth E, Qwarnstrom EE, Dower SK, Hidvégi M, Duda E, Nagy T: Synergistic effect of Avemar on proinflammatory cytokine and ras mediated cell activation. 1st Congress of the Hungarian Society of Clinical Oncology, Budapest, Hungary, 10 - 11 November, 2000.
Click to view full text
25. Pethig R, Gascoyne PRC , Mclaughlin JA, Szent-Gyorgyi A: Enzyme-controlled scavenging of ascorbyl and 2,6-dimethoxysemiquinone free radicals in Ehrlich ascites tumor cells, Proc. Natl. Acad. Sci. USA, Cell Biology March 1985, Vol. 82, pp. 1439-1442.
Click to view full text
26. Pethig R, Gascoyne PRC , Mclaughlin JA, Szent-Gyorgyi A: Interaction of the 2,6-dimethoxysemiquinone and ascorbyl free radicals with Ehrlich ascites cells: A probe of cell-surface charge, Proc. Natl. Acad. Sci. USA, Cell Biology April 1984, Vol. 81, pp. 2088-2091.
Click to view full text
27. Pethig R, Gascoyne PRC , Mclaughlin JA, Szent-Gyorgyi A: Ascorbate-quinone interactions: Electrochemical, free radical, and cytotoxic properties, Proc. Nati Acad. Sci. USA, Biochemistry January 1983, Vol. 80, pp. 129-132.
Click to view full text

Avemar is a registered trademark of Biromedicina Rt., Budapest, Hungary